HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $7.00 target price on the stock.

Several other research analysts have also weighed in on KPTI. StockNews.com upgraded shares of Karyopharm Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, August 8th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. Finally, Robert W. Baird decreased their price target on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an "outperform" rating on the stock in a report on Wednesday, August 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Karyopharm Therapeutics has an average rating of "Buy" and a consensus price target of $5.00.

Karyopharm Therapeutics Price Performance

KPTI traded down $0.09 during trading on Friday, hitting $0.90. The company's stock had a trading volume of 1,697,228 shares, compared to its average volume of 1,276,340. Karyopharm Therapeutics has a twelve month low of $0.62 and a twelve month high of $1.95. The stock has a market cap of $112.61 million, a PE ratio of -0.83 and a beta of 0.20. The firm's 50 day moving average price is $0.80 and its 200-day moving average price is $0.92.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. The business had revenue of $42.79 million during the quarter, compared to analyst estimates of $36.07 million. Equities analysts anticipate that Karyopharm Therapeutics will post -0.95 earnings per share for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Several large investors have recently made changes to their positions in KPTI. Ikarian Capital LLC grew its stake in shares of Karyopharm Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company's stock valued at $618,000 after buying an additional 9,355 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $31,000. Exchange Traded Concepts LLC grew its position in Karyopharm Therapeutics by 34.9% in the third quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company's stock valued at $182,000 after acquiring an additional 56,613 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at approximately $143,000. Finally, Acadian Asset Management LLC acquired a new position in shares of Karyopharm Therapeutics during the second quarter worth $167,000. Institutional investors and hedge funds own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).